PARIS, Dec. 4, 2017 /PRNewswire-USNewswire/ -- Sanofi's Toujeo® met the primary study objective in the first large head-to-head clinical trial 1, called BRIGHT study, comparing Toujeo with insulin ...

The European Union has given the nod to a new formulation of insulin glargine (Toujeo, Sanofi), which is a higher-strength insulin (300 units/mL) than the existing insulin glargine product on the ...

The FDA on February 25, 2015, approved the basal insulin Toujeo, which Sanofi sees as a successor to Lantus to treat patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM). Toujeo, insulin ...

Sanofi’s newest insulin met its primary objective in a large head-to-head trial that compared it with its chief competitor. Sanofi’s newest insulin, Toujeo, met its primary objective in a large ...

Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo ® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve ...

LISBON, Portugal—Sanofi’s longer-acting basal insulin Toujeo, a follow-up to its own long-dominant product Lantus, beat the older medication at holding off hypoglycemia, both by day and by night. In ...

PARIS, Feb. 25, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that the U.S. Food and Drug Administration (FDA) approved Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk ...

Study patients who switched to Toujeo were 57% less likely to have hypoglycemia at the 6-month follow-up (OR 0.432, 95% CI: 0.307-0.607; P Findings from a real-world observational study showed a ...

SAN DIEGO—Sanofi’s Toujeo has plenty of competition in the basal insulin market, but new real-world data shows it may outdo its peers at cutting the risk of hypoglycemia for older patients. And Sanofi ...

After six months, patients who switched to Toujeo had 33% less hypoglycemic events compared to those who switched to other basal insulins without compromising blood sugar control. Sanofi announced new ...

PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that, in a pooled analysis, investigational therapy Toujeo ® (insulin glargine [rDNA origin] injection, 300 ...